Cardiovascular and Renal Risk in Spain

Identificación de la poBlación Española de RIesgo CArdiovascular y reNal

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02261441

Acronym

IBERICAN

Enrollment

15000

Registered

2014-10-10

Start date

2014-02-28

Completion date

2019-02-28

Last updated

2017-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

Cardiovascular disease, Hypertension, Diabetes, Smoking, Hypercholesterolemia, Cardiovascular risk factor

Brief summary

IBERICAN is a multicenter, longitudinal and observational population-based study of patients daily attended in Primary Care setting in Spain. This study is aimed to determine the prevalence and incidence of cardiovascular risk factors in adult population in Spain. Patients will be followed-up for a minimum period of 5 years, every 6 months or a lesser period when clinically required. It has been estimated that a total of 15,000 individuals will be included.

Detailed description

IBERICAN (Identificación de la poBlación Española de RIesgo CArdio Vascular y reNal) is a multicenter, longitudinal and observational population-based study of patients daily attended in Primary Care setting in Spain. The aims of IBERICAN are to determine the prevalence and incidence of cardiovascular risk factors in adult population in Spain. Moreover, the development of cardiovascular outcomes, and risk factors control rates will be also analyzed. In IBERICAN, subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment. The study has been approved by the ethic committee of Hospital Carlos III, Madrid on February 2013. Before inclusion, every patient will provide a written informed consent. Patients will be followed-up for a minimum period of 5 years, every 6 months or a lesser period when clinically required. Excepting a blood analysis in the previous 6 months before the inclusion, no other specific diagnostic tool or technique will be required for being included in the study. All blood and urine analysis or other techniques will be performed according to clinical practice during the follow-up. It has been estimated that a total of 15,000 individuals will be included.

Interventions

OTHERObservational and noninterventional study

No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* National Health Care System user. * Resident at Spain in the last 5 years. * Attended by investigator in Primary Care setting.

Exclusion criteria

* Change of regular residence to other city or country in the following 6 months. * Life expectancy less than 5 years. * Difficult to follow-up.

Design outcomes

Primary

Measure	Time frame	Description
Cardiovascular event	5 years	Development of cardiovascular events.
Cardiovascular risk factors	5 years	Development of cardiovascular risk factors.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026